Monoclonal antibody therapy and anti-viral pills have become important tools in reducing hospitalizations from COVID-19. But their availability shouldn’t be used as a reason to forego ...

"I woke up like somebody gave me a happy pill." Monoclonal antibodies, which provide extra immune soldiers to help the body fight off COVID-19, are aimed at people such as Ramirez, who are at high ...

A new scientific discovery is offering a promising breakthrough for people struggling with hay fever and asthma triggered by pollen. Scientists have found a way to stop allergic reactions caused by ...

For COVID-19 therapies, there is limited supply and high demand, meaning it is difficult for most to access new antiviral pills and monoclonal antibodies. Prescription-only antiviral drugs ...

Both the antiviral pills and the monoclonal antibody infusions must be taken soon after a COVID-19 diagnosis to be effective. The pills must be taken within five days and the antibodies given ...

Vaccines are the focus of the global fight against COVID-19, but a flurry of therapeutic breakthroughs and fights over limited supplies of antibody drugs are returning treatments back to the spotlight ...

COVID-19 pills and monoclonal antibody treatments are designated for use in the first few days of coronavirus infection for patients at high-risk of severe illness from the virus.

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the double-digit millions, milestone payments, and research and development funding.